MAO-B inhibitors for the treatment of Parkinson’s disease

Research output: Chapter in Book/Report/Conference proceedingChapter


Monoamine oxidases (MAO) are crucial enzymes that oxidatively deaminate monoamines (amines that have only one amino group, such as serotonin, epinephrine, norepinephrine, dopamine, tyramine, and tryptamine). There are two main forms of MAO. MAO-A predominates in the gut, spleen, and pancreas, and especially the placenta, and is inhibited by clorgyline [1]. MAO-B predominates in the human brain, skin, and skeletal muscle and is inhibited by deprenyl and pargyline [1]. Recent reviews of MAO inhibitors (MAOI) are available [2].

Original languageEnglish (US)
Title of host publicationParkinson's Disease, Second Edition
PublisherCRC Press
Number of pages14
ISBN (Electronic)9781439807156
ISBN (Print)9781439807149
StatePublished - Jan 1 2012

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)


Dive into the research topics of 'MAO-B inhibitors for the treatment of Parkinson’s disease'. Together they form a unique fingerprint.

Cite this